Skip to main content
IMS Events Main banner
Back

    Xavier P. Leleu, MD, PhD (he/him/his)

    Head of Myeloma Clinic and Head of Department of Haematology
    Hospital La Mileterie, Poitiers, France
    Poitiers, France

    Xavier Leleu is Professor, Head of the Myeloma Clinic and Head of the Department of Hematology at Hôpital La Mileterie. He collaborates closely with the Immunology fundamental lab U Inserm 1313, and heads the Thor axis early phase clinical research team at CIC U Inserm 1082. part of the academic hospital of Poitiers (Centre Hospitalier Universitaire), Poitiers, France.
    Professor Leleu received his medical degree at the University of Bordeaux, France. He completed his specialisation in public healthcare and statistics at the University of Medicine of Paris, France and in haematology at the University of Medicine of Lille. Professor Leleu was the head of the Myeloma Clinic in Lille under Professor T Facon’s mentorship for almost 15 years. He received a Master’s degree in cellular biology at the University of Medicine of Lille in 2001 and completed his PhD in 2007, having studied at Dana-Farber Cancer Institute, affiliated with Harvard Medical School, Boston, MA, USA. His main topic of research was the preclinical development of novel agents and understanding mechanisms of resistance and of dormancy in Waldenström macroglobulinaemia and the clinical development of novel agents in multiple myeloma in the context of the most recent discoveries in the biology of myeloma. He was trained with his mentors Dr IM Ghobrial and Dr SP Treon in Prof. Kenneth Anderson’s laboratory.
    Pr Leleu is a member of the board of director of the IFM (Intergroupe Francophone of Multiple Myeloma).
    Professor Leleu’s current research is focused on treatment methods in multiple myeloma, incorporating emerging immunology and immunotherapy approaches to shift the future treatment paradigm to improve patient outcomes. Professor Leleu maintains a special interest in research relating to cure within the multiple myeloma field.

    Disclosure information not submitted.

    Presentation(s):